01 January 1998
Class I HLA in patients suffering from tuberculosis - population analysis
Anna Dubaniewicz, Zofia SzczerkowskaMed Sci Monit 1998; 4(1): CR122-126 :: ID: 502841
Abstract
The aim of the present study was the analysis of the relation between the incidence of tuberculosis and particular class I HLA among patients of hospitals in Gdańsk, Gdynia and Sopot. 115 patients with active tuberculosis were included in the examination of HLA from A, B, C locus. The diagnosis of tuberculosis was confirmed bacteriologically by the detection of Mycobacterium tuberculosis in sputum cultures. The control group consisted of 100 healthy, unrelated adults. The examination of class I antigens was performed according to microlymphocytotoxic NIH test by Terasaka. χ2 test was used for statistical analysis with the confidence level of p<0.05, with the use of Yates' modification. The relative risk was calculated according to Woolf's method. The significantly increased value of the test for HLA-B62(15) (χ2=4.1; p<0.05; RR=2.85) and HLA-Cw5 (χ2=3.86; p<0.05; RR=6.72) was found in tuberculosis on the basis of our results. However we found significantly decreased values of χ2 test among patients suffering from tuberculosis with relative risk RR<1 for antigens: HLA-A2 (χ2&eguals;6.8; p<0.001), -A10 (χ2=72.45; p<0.0001), -A26 (10) (χ=4.03; p<0.05), -A11 (χ2=4.36; p<0.05), -B40 (χ2=25.4; p<0.0001), -B7 (χ2=4.75; p<0.05), -Cw1 (χ2=4.1; p<0.05). On the basis of these results it was concluded that: 1. In the population of patients suffering from tuberculosis, living in the area of North Poland antigens HLA-62(15) and HLA-Cw5 were found significantly more frequently in comparison with control group of healthy people. 2. In the examined group of patients antigens HLA-A2, -A26(10), -A11, -B7, -B40, -Cw1 were found significantly less frequently in comparison with the control group.
Keywords: Tuberculosis, HLA-C, HLA-B, HLA-A
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952